Plant Name: Agrimonia pilosa
Taxonomic Information:
Plant ID: NPO18007
Plant Latin Name: Agrimonia pilosa
Taxonomy Genus: Agrimonia
Taxonomy Family: Rosaceae
Plant External Links:
NCBI TaxonomyDB:
74656
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; South Korea; India; RussiaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Analgesic; Antibacterial; Antiinflammatory; Antipyretic; Astringent; Cardiotonic; Haemostatic; Hypoglycaemic; Vasoconstrictor; Vermifuge
Geographical Distribution:
India; South Korea; China; Russia
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; GPR35; | |
| NPSR1; | |
| TDP1; RECQL; HSD11B1; ALOX12; HSD17B1; AKR1B1; HSD17B2; HSD17B10; NOX4; HPGD; ALOX15; APEX1; POLB; | |
| ACHE; | |
| CDC25B; | |
| TEK; KDR; INSR; EGFR; MET; AXL; FLT3; CDK1; PIM1; SRC; IGF1R; AURKB; NUAK1; CSNK2A1; | |
| CA2; CA12; CA7; CA4; | |
| PPARA; | |
| RORC; | |
| NR1H4; | |
| ESR2; | |
| TYR; | |
| KDM4E; | |
| MMP12; MMP9; MMP1; MMP2; | |
| AHR; HIF1A; NFKB1; | |
| FUT7; | |
| SLC22A6; | |
| LMNA; FABP3; FABP5; SMAD3; FABP4; THPO; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.662E-09 | 2.828E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.094E-08 | 3.665E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.725E-08 | 1.040E-05 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK, THPO |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.035E-07 | 2.398E-05 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, SMAD3, TEK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.455E-07 | 3.201E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.765E-07 | 3.705E-05 | CYP1A1, HIF1A, LMNA, MMP2, NOX4, PPARA, SMAD3, SRC, TEK |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.159E-07 | 4.354E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.757E-07 | 5.265E-05 | ALOX15, EGFR, FFAR4, KDR, NOX4, SRC, TEK, THPO |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 4.692E-07 | 7.982E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.803E-07 | 9.646E-05 | AHR, ESR2, NR1H4, PPARA, RORC |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.805E-07 | 1.452E-04 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.756E-06 | 2.263E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.787E-06 | 2.286E-04 | AHR, ESR2, NR1H4, PIM1, PPARA, RORC, SRC |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.816E-06 | 2.286E-04 | FABP3, FABP4, FABP5, FFAR4 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.828E-06 | 2.288E-04 | AHR, AXL, EGFR, ESR2, FFAR1, FFAR4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, PPARA, RORC, TEK |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.125E-06 | 2.614E-04 | CA12, CA2, CA4, CA7, ESR2, MMP1, MMP12, MMP2, MMP9, NR1H4, PPARA, RORC, SMAD3 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.227E-06 | 2.710E-04 | APEX1, CYP1A1, CYP1B1, EGFR, FLT3, NFKB1, NOX4, RORC, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.873E-06 | 3.363E-04 | EGFR, INSR, KDR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.675E-06 | 4.042E-04 | AHR, CSNK2A1, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.095E-06 | 4.392E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 5.249E-06 | 5.469E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.961E-06 | 6.094E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 9.109E-06 | 9.140E-04 | ACHE, EGFR, HSD17B1, IGF1R, INSR |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 9.646E-06 | 9.504E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 9.689E-06 | 9.504E-04 | CYP19A1, HSD17B1, HSD17B2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 9.646E-06 | 9.504E-04 | CYP3A4, ESR2, HSD17B1, NR1H4, RORC |
| MF | Unclassified; | GO:0032403; protein complex binding | 9.951E-06 | 9.717E-04 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP12, MMP9, PPARA, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.081E-05 | 1.032E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.081E-05 | 1.032E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.081E-05 | 1.032E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 1.227E-05 | 1.161E-03 | AXL, HIF1A, HSPA1A, MMP12 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.243E-05 | 1.161E-03 | ACHE, EGFR, FFAR1, HIF1A, MMP12, NR1H4, SRC |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.347E-05 | 1.243E-03 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.821E-05 | 1.645E-03 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.884E-05 | 1.694E-03 | ALOX12, ALOX15, HPGD |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.668E-05 | 2.243E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.235E-05 | 2.571E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.235E-05 | 2.571E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.235E-05 | 2.571E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.235E-05 | 2.571E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 3.292E-05 | 2.588E-03 | CDK1, EGFR, IGF1R, INSR |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.468E-05 | 2.707E-03 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 3.787E-05 | 2.889E-03 | ALOX15, EGFR, MMP2, MMP9, TEK |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 4.350E-05 | 3.255E-03 | ESR2, NR1H4, PPARA, RORC |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.421E-05 | 3.297E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 4.517E-05 | 3.357E-03 | ALOX15, HSPA1A, MET, NOX4, SMAD3, TEK |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 5.107E-05 | 3.745E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.860E-05 | 4.187E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 6.376E-05 | 4.513E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.457E-05 | 4.513E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 6.466E-05 | 4.513E-03 | AKR1B1, APEX1, IGF1R, INSR, NFKB1, SRC |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.457E-05 | 4.513E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 7.090E-05 | 4.780E-03 | ESR2, NR1H4, PPARA, RORC, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 7.090E-05 | 4.780E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.438E-05 | 4.999E-03 | AHR, AKR1B1, APEX1, AURKB, CDC25B, CDK1, CSNK2A1, ESR2, FABP5, HIF1A, HPGD, HSPA1A, LMNA, NFKB1, NR1H4, NUAK1, PIM1, POLB, PPARA, RECQL, RORC, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 7.574E-05 | 5.059E-03 | FABP3, FABP4, FABP5 |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 7.807E-05 | 5.167E-03 | AHR, APEX1, EGFR, ESR2, HIF1A, NFKB1, NR1H4, PPARA, RORC, SMAD3, TDP1 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 8.542E-05 | 5.602E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.074E-04 | 6.817E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.074E-04 | 6.817E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 1.150E-04 | 7.249E-03 | APEX1, CDC25B, CDK1, CYP1A1, INSR |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.152E-04 | 7.249E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.192E-04 | 7.394E-03 | AXL, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.237E-04 | 7.609E-03 | ALOX15, EGFR, PPARA, SMAD3 |
| MF | GO:0005488; binding | GO:0035257; nuclear hormone receptor binding | 1.308E-04 | 7.955E-03 | FLT3, HIF1A, NR1H4, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.321E-04 | 7.992E-03 | FLT3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.367E-04 | 8.221E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.435E-04 | 8.537E-03 | FABP3, FFAR1, NR1H4, SRC |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.459E-04 | 8.589E-03 | CYP1A2, EGFR, MMP9 |
| BP | GO:0032502; developmental process | GO:0048732; gland development | 1.485E-04 | 8.691E-03 | CSNK2A1, CYP19A1, EGFR, INSR, SMAD3, TYR |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.575E-04 | 9.194E-03 | ALOX12, CYP1B1, HIF1A, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.588E-04 | 9.219E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.607E-04 | 9.283E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.607E-04 | 9.283E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:1901989; positive regulation of cell cycle phase transition | 1.733E-04 | 9.879E-03 | APEX1, CDC25B, CDK1, CYP1A1 |
| BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.763E-04 | 9.945E-03 | HIF1A, PPARA, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.763E-04 | 9.945E-03 | INSR, PPARA, SRC |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.181E-11 | 1.795E-09 | HSD11B1, HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.197E-10 | 1.669E-08 | HSD17B1, INSR, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.727E-09 | 1.889E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.669E-07 | 6.761E-06 | SRC, MMP2, KDR, HIF1A, MMP9, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.944E-07 | 1.074E-05 | SMAD3, FLT3, MMP1, MMP2, HIF1A, MET, MMP9, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.962E-07 | 6.686E-06 | MMP1, SRC, MMP2, MMP9, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.504E-07 | 1.426E-05 | SRC, MMP2, MMP9, EGFR, ESR2, HSPA1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.481E-07 | 1.601E-05 | INSR, TEK, HIF1A, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.914E-06 | 6.224E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.932E-06 | 8.612E-05 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.635E-06 | 5.023E-05 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.747E-06 | 4.175E-05 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.865E-05 | 1.890E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.199E-07 | 6.686E-06 | CA12, CA2, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.459E-06 | 7.552E-05 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.468E-05 | 3.995E-04 | PIM1, CYP1B1, MMP9, MET, EGFR, NFKB1, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.378E-05 | 2.259E-04 | HPGD, FLT3, MMP9, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.063E-04 | 7.789E-04 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.260E-04 | 8.709E-04 | ALOX15, AKR1B1, ALOX12, CYP3A4, TYR, CYP19A1, HSD17B10, HSD11B1, FUT7, HSD17B1, HSD17B2, CYP1A2, CYP1A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 6.282E-05 | 5.305E-04 | FLT3, MET, HIF1A, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.659E-05 | 5.327E-04 | SRC, MET, EGFR, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.085E-04 | 1.954E-03 | SMAD3, MMP2, PIM1, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 4.703E-04 | 2.859E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 8.721E-04 | 4.910E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.233E-03 | 5.883E-03 | SMAD3, SRC, MMP9, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 8.084E-04 | 4.726E-03 | FLT3, PIM1, NFKB1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 1.586E-03 | 6.724E-03 | THPO, FLT3, KDR, MET, EGFR |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.133E-03 | 5.883E-03 | INSR, HSPA1A, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.837E-04 | 1.875E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.239E-03 | 5.883E-03 | SMAD3, EGFR, NFKB1 |
| 09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 1.185E-03 | 5.883E-03 | SMAD3, RORC, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.530E-03 | 6.724E-03 | MET, EGFR, IGF1R |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.185E-03 | 5.883E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.592E-03 | 6.724E-03 | SRC, NFKB1, ESR2 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.530E-03 | 6.724E-03 | CA2, NR1H4, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.076E-04 | 7.789E-04 | CYP1A2, ALOX15, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; MMP2; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; INSR; FFAR1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; INSR; AKR1B1; FFAR1; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; INSR; EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; HSD11B1; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; MMP1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; INSR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; TEK; MMP9; EGFR; SRC; MMP2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; TEK; MMP9; EGFR; SRC; MMP2; CDC25B; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; MMP1; TYR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; INSR; EGFR; CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NFKB1; INSR; FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
